Short answer
Denali Therapeutics Inc. (DNLI) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 financial results for quarter ended March 31, 2026.
Denali Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results for quarter ended March 31, 2026
- Press release in Exhibit 99.1 contains financial figures and management commentary
- Investor focus: cash position, operating expenses, pipeline progress, and development funding implications
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Denali Therapeutics Inc. 8-K filings
Get the next DNLI 8-K as it lands
Follow DNLI for push alerts, or ask the research agent what this filing means.